secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viatris Inc (VTRS)
CIK:        0001792044
Form:       8-K
Filed at:   2024-06-03T23:59:59+00:00
Accession:  0001193125-24-152351
Event type: leadership
Sentiment:  positive
Materiality: 0.35
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Viatris appoints Dr. Rogério Vivaldi Coelho to Board of Directors
-----------------------------------------------------------------

- Appointment effective June 3, 2024; expands Board from 11 to 12 members.
- Dr. Vivaldi joins the reestablished Science and Technology Committee.
- Former CEO of Sigilon Therapeutics (acquired by Eli Lilly, 2023) and executive at Bioverativ, Spark Therapeutics, and Genzyme.
- Led successful approval of more than 15 orphan products across 20+ countries during Genzyme tenure.
- Will receive standard compensation for non-employee directors; indemnification agreement executed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1792044/000119312524152351/0001193125-24-152351-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1792044/000119312524152351/d832479d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-152351

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer